QUOTED. 18 June 2021. Harith Rajagopalan.
Fractyl Health closed a $100m financing round to support ongoing development of duodenal mucosal resurfacing (DMR) technology that addresses root causes of type 2 diabetes. CEO Harith Rajagopalan spoke of his hopes for the technology.
“We’ve seen from the clinical work that we’ve done that Revita has the potential to be a ‘backbone’ therapy in type 2 diabetes and other metabolic diseases.” – Harith Rajagopalan, CEO, Fractyl Health
Click here for a free trial of Medtech Insight